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Objectives: The surgical site infection (SSI) is the most often acquired hospital 
infection in Spain, about 19.4% of all nosocomial infections. The prevalence of this 
adverse event is 8.01%, generating high economic impact on hospital costs and 
undermining the quality of care. The risk of SSI has increased in recent years and 
infections have become more resistant to treatments. About 50% of SSIs are pre-
ventable, their costs are avoidable, and health technology can help avoiding them. 
The aim of this study is to analyze the economic impact that could represent the 
use of anti-bacterial sutures compared with conventional ones in Spanish hospi-
tals. MethOds: An interactive Excel model was developed using data obtained 
through a published literature review. The rate of reduction of SSI with antibacte-
rial suture is 30%. The incremental cost per patient with SSI is between € 9,657 and 
€ 10,112.63. Two scenarios were designed: 100% of surgeries with normal sutures and 
100% of surgeries with anti-bacterial sutures. A sensitivity analysis for the variables 
of greatest uncertainty was performed (cost per SSI). Results: The budget impact 
of the use of antibacterial sutures resulted in a 24% of cost savings related to the 
normal sutures. It represents savings of € 5.4M per year for an average Spanish 
hospital, and € 1,264M per year for the whole Spanish Health System. The results of 
the sensitivity analysis shows that even by changing the effectiveness of the suture 
and using the most unfavourable data found in the literature for the cost of an SSI, 
the use of the antibacterial suture still produces savings of 24% compared with the 
use of normal suture. cOnclusiOns: This budget impact analysis provides new 
evidence that reinforces the use of antibacterial sutures, because it may reduce 
the risk of SSI, the negative effects of its consequences and associated costs and 
significantly improving the quality of care for surgical patients in Spain.
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Objectives: The 2013 WHO-guidelines recommend viral load (VL) monitoring plus 
CD4-count monitoring for patients on antiretroviral treatment (ART) in resource-
limited settings. We calculated the budget impact (BI) of VL monitoring strategies 
at the Infectious Diseases Institute (IDI), a large urban HIV program in Kampala, 
Uganda. MethOds: We calculated cost for the first 2 years of ART (drugs/tests/
staff) for three strategies: (1) Immunologic monitoring, standard of care (SOC): 
6-monthly CD4-count (2) New WHO-guidelines: SOC plus 6-monthly VL (3) A novel 
strategy: exclusive-VL (no CD4-counts after ART start), with VL at 3-months (to 
support adherence monitoring) and at 24 months. Patients with VL > 400copies/ml 
VL at 3-months will receive adherence counseling and repeat VL at 6-months. All 
costs are current actual costs at IDI and presented as 2012 USD ($): CD4-count= $9; 
VL= $65; first-line patients $206/year in year-1 and $272/year in year-2; second-line 
patients= $1381/year. For each strategy, rates of switch to second-line were estimated 
using IDI clinic data (1) SOC: 27%, 29%, 32% at 6, 12, 18 months (2) WHO-guidelines: 
7.3%, 10.8%, 13.8% at 6, 12, 18 months (3) Exclusive-VL: 21% at 3 months, 8.3% at 
6 months. Results: The cost per patient for the first 2 years of ART and BI of VL 
monitoring are (1) SOC: $572 (2) WHO- guidelines $897, BI $325 (3) Exclusive VL: 
$720, BI $148. Exclusive VL-monitoring results in a lower BI by supporting adher-
ence and averting ART failure. Increased cost with VL-monitoring is driven by more 
patients switching timely to second-line treatment with the cost of 2nd-line patients 
being 3.6 times higher for the new WHO-guidelines and 2.8 times higher for the 
exclusive-VL compared to SOC, rather than VL tests. cOnclusiOns: Implementing 
VL-monitoring strategies result in modest BI (26%-57%). Since switching timely to 
second-line benefits patients, similar programs should consider allocating resources 
to VL monitoring.
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Objectives: Invasive pneumococcal disease (IPD) is a major public health chal-
lenge. This study aims to perform a budget impact analysis (BIA) of 13-valent 
pneumococcal conjugated vaccine (PCV13) in adults immunocompromised (IC) or 
with comorbidities (CM), from a public payer perspective in Brazil. MethOds: BIA 
using a Markov model framework estimated the incremental costs of a vaccination 
program over a 10 year period comparing PCV13 versus PPSV23 or no vaccination 
in adults ≥ 18 years with CM or IC. Population size was calculated from Brazilian 
Institute of Geography and Statistics (IBGE) projections for 2014-2023 period and 
prevalence of risk groups were extracted from literature. Efficacy data for PCV13 
and PPSV23 were based on published data. Direct medical costs obtained from the 
literature included hospital days, medical fees, outpatient visits, diagnostic tests, 
and drugs in Brazilian Real (BRL). PCV13 and PPSV23 costs per dose were 52.40BRL 
and 23.00BRL, respectively. Results: Eligible population consisted of 15,241,353 
(CM) and 1,305,794 (IC) patients, for the 10-year period. After vaccination with PCV13, 
111, 869 (CM) and 42,786 (IC) IPD cases were avoided versus PPSV23 and 110,208 (CM) 
and 40,224 (IC) IPD cases versus no vaccination. Incremental costs per patient were 
52.02BRL (CM), and 51.92BRL (IC), for vaccination with PCV13 versus non vaccination, 
leading to a budget impact of 793,005,843BRL (CM) and 67,805,835 (IC) for the 10-year 
into single estimates (with confidence intervals for sensitivity analyses). The pur-
pose of this study is to investigate various methodologies for synthesizing data 
used as inputs into an economic model, based on a systematic review of a specific 
disease incidence. MethOds: A random-effects meta-analysis was conducted to 
estimate herpes zoster incidence from a systematic literature review of herpes 
zoster incidence in Europe. Since incidence could potentially be explained by some 
study-specific characteristics meta-regression was investigated. The variable of 
interest was predicted based on the year of data collection, country, age-group and 
study design. As incidence (expressed as annual probability) is typically bounded 
by 0 and 1, a logistic function was used to model the link between the predicted 
variable and its predictors. Results: Statistical tests suggested that data from 
some studies were outliers and were thus inconsistent with the model. A significant 
positive correlation was observed between age and herpes zoster incidence. The 
model allows for trends in incidence data to be explored based on country, year of 
data collection, study design and age. cOnclusiOns: This project investigated 
the use of meta-analysis and meta-regression for synthesizing data coming from 
various sources identified through a systematic review. Limitations were identified 
for both approaches. However, the meta-regression analysis can be used to estimate 
the current incidence of a particular disease, for a specific age group and country. 
It could help health economists in populating models and, subsequently, decision 
makers in their evaluation and assessments.
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Objectives: Development of highly active antiretroviral treatment (ART) had 
revolutionized the care of Human Immunodeficiency virus (HIV) -infected patients 
and led to marked reductions in HIV-associated morbidity and mortality in many 
developed countries. Hence this study aimed to analyze the predictors for mortal-
ity among patients living with HIV and who are on Antiretroviral Therapy (ART) in 
a south Indian hospital. MethOds: A retrospective cohort study was conducted 
on 350 patients infected with HIV were admitted to Asha Kirana Hospital, Mysore-
South India for a period of three years. Patients who died in the hospital during 
the study period (n-80) were compared with patients who had survived (n-270). 
Both groups were matched for age and sex. Predictors for death were analyzed by 
chi-square test using bivariate regression in software SPSS version 21. Results: 
Predictors for death in this study were increasing age > 60 years (RR), (95% CI) 2.204, 
(1.15-4.21), CD4 count < 200 cells 2.14 (1.26-3.13), patients without opportunistic 
infections- 1.80 (1.23- 2.63), WHO stage IV 1.83 (1.25-2.67) and being on stavudine 
based ART 2.01 (1.44-2.81). Patients with under-weight 1.33 (0.88-1.99) also found 
be risk for mortality, but it is not statistically significant. Factors associated with 
survival benefit were female sex 0.81 (0.55-1.19), patients without ART toxicity 0.78 
(0.51-1.20) and being on Tenofovir based regimen 0.8 (0.79-0.96). cOnclusiOns: 
Predictors for mortality among HIV patients on ART were found to be patients age 
> 60 years, CD4 count < 200 cells, WHO stage IV, absence of opportunistic infec-
tions and patients on Stavudine therapy. The absence of opportunistic infections 
being a risk factor may be due to undiagnosed opportunistic infections due to 
limited diagnostic facility as in this study setting. Patients on Tenofovir having 
survival benefit support the 2013 WHO recommendation for Tenofovir being the 
preferred regimen.
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Objectives: The rapid global spread of multi-resistant bacteria and loss of anti-
biotic effectiveness increases the risk of initially inappropriate antibiotic therapy. 
We examined the effects of use of appropriate or inappropriate antibiotic ther-
apy on outcomes in Gram-negative infections. MethOds: We searched Medline, 
Cochrane Central, and Embase databases through March 2014 for English-language 
studies that quantified effects of use of appropriate or inappropriate antibiotic 
therapy on all-cause mortality, length of stay, hospital costs, treatment failure, or 
bacterial clearance in hospitalized patients with complicated urinary tract infec-
tion, complicated intra-abdominal infection, bacteremia and pneumonia due to 
Gram-negative pathogens. We screened citations in duplicate and resolved dif-
ferences by consensus. We used random effect models meta-analysis when at 
least 3 studies reported the same outcome. Results: Forty-five studies with 1895 
patients were eligible. The definition of initial appropriate antibiotic therapy varied 
across studies. In meta-analyses of unadjusted data, initial appropriate antibiotic 
therapy was associated with lower risk of mortality (26 studies, 3713 patients, odds 
ratio (OR) 0.52, 95% confidence interval (CI) 0.41– 0.66) and treatment failure (3 
studies, 283 patients, OR 0.22, 95% CI 0.14– 0.35). In meta-analyses of adjusted data, 
initial appropriate therapy was associated with lower risk of mortality (5 studies, 
1211 patients, OR 0.50,95% CI 0.25–1.00), and conversely, initial inappropriate ther-
apy increased risk of mortality (16 studies, 2493 patients, OR 3.30, 95% CI 2.42–4.49) 
and decreased bacterial clearance. There were insufficient data to evaluate the 
impact on resource utilization and economic outcomes. cOnclusiOns: Initial 
inappropriate therapy is associated with an increased risk of hospital mortality. 
The paucity of new and effective antibiotics to cover resistant Gram-negative 
pathogens increases the likelihood of initial inappropriate therapy and poses a 
serious threat to patient safety. Critical gaps include lack of information on the 
health and economic burden of resistance.
